Risk of schizophrenia assessed with new screening tool (Links to an external site)
16-question tool designed to identify young people at high risk
Promoting resilience in health-care workers aim of new grant (Links to an external site)
WashU receives part of $103 million to address depression, anxiety related to pandemic
WashU part of $65 million NIH study of schizophrenia in young people (Links to an external site)
Teens, young adults needed for study aimed at improving early diagnosis
Antidepressant may prevent severe COVID-19, follow-up study indicates (Links to an external site)
Low-cost drug lowers risk of hospitalizations, deaths
Older people’s resilience during pandemic focus of $9 million grant (Links to an external site)
Research to explore the effects of social isolation on cognitive, emotional health
$12.2 million to fund new Conte Center to study neurosteroids (Links to an external site)
Complements efforts of Taylor Family Institute to develop treatments for psychiatric illness
$6.2 million grant to fund Center for Perioperative Mental Health (Links to an external site)
Researchers to study ways to improve mental health for surgery patients
Dr. Mamah Announced the 2021 Recipient of the Dr. John M. Anderson Excellence in Mental Health Award
Dr. Daniel Mamah was announced as this year’s recipient of the 2021 Dr. John M. Anderson Excellence in Mental Health Award. The St. Louis County Children’s Service Fund honors a mental healthcare professional each year who has made significant contributions in the field of behavioral health. Dr. John M. Anderson was an African American psychiatrist […]
Laughing gas relieves symptoms in people with treatment-resistant depression (Links to an external site)
Researchers at Washington University School of Medicine in St. Louis and the University of Chicago have found that a single, one-hour treatment that involves breathing in a mixture of oxygen and the anesthetic drug nitrous oxide — otherwise known as laughing gas — can significantly improve symptoms in people with treatment-resistant depression.
Finding a possible early treatment for COVID-19 in a 40-year-old antidepressant (Links to an external site)
Sharyn Alfonsi reports on the unusual path fluvoxamine, a drug commonly used to treat obsessive-compulsive disorder, has had to becoming an early treatment candidate for COVID-19
Fluvoxamine may prevent serious illness in COVID-19 patients (Links to an external site)
Antidepressant drug repurposed for patients with coronavirus infection
Barch, Bateman elected to National Academy of Medicine (Links to an external site)
Research into psychological disorders, Alzheimer’s disease earned the two one of the most prestigious honors in health, medical field